Argus
•
Nov 04, 2026
Pfizer Inc.: Raising target to $40
Summary
Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: GE Aerospace
Nov 05, 2026
•
GE
Analyst Report: The Walt Disney Company
Nov 05, 2026
•
DIS
Analyst Report: Bristol-Myers Squibb Co
Nov 04, 2026
•
BMY
Market Update: BKNG, AMD, BMY, MMM, OKE, PFE, WMB, ANET
Nov 04, 2026
•
ANET, AMD, OKE, MMM, WMB, BKNG, PFE, BMY
Analyst Report: Amgen Inc.
Nov 04, 2026
•
AMGN
Analyst Profile
David H. Toung
Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.
